Dermatology Times January 2026 Print Recap

The January issue of Dermatology Times includes a collection of thought-provoking articles and topics as we explore insights into the psychosocial burden of psoriasis, upcoming research on GLP-1s for dermatological diseases, and a preview of this year’s aesthetic trends.

Don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplement each month.

Beyond the Plaques: How Psoriasis Shapes Work, Relationships, and Social Health

For more than 7.5 million adults in the US with psoriasis—roughly 3% of the adult population—psoriasis is far more than a visible irritation. It is a chronic inflammatory disease that silently affects the whole body, touching physical health, emotional well-being, and social life in ways that need to be addressed.

According to the National Psoriasis Foundation’s 2024 Psoriasis Health Indicator Report, severe cases are linked to a 46% higher risk of cardiovascular disease, along with increased chances of stroke, heart attack, and metabolic disorders such as diabetes and obesity. People with severe psoriasis may die years earlier than those without the disease, with men losing an average of 3.5 years of life and women 4.4 years. The inflammation that produces skin lesions also impacts blood vessels and internal organs, making it a silent but serious threat to overall health.

Read more

Highlighting Upcoming Aesthetic Innovations in 2026

The leading theme at the recent American Society for Dermatologic Surgery Annual (ASDS) Meeting in Chicago, Illinois, was momentum. Dermatology clinicians were consistently discussing smarter resurfacing, tighter skin, regenerative treatments, and a noticeable shift toward aesthetic work that looks completely undetectable. To understand what is truly resonating with clinicians and patients, Dermatology Times' sister brand, NewBeauty, interviewed 3 leading experts.

Read more from Tina Alster, MD; Daniel Schlessinger, MD; and Mary Lupo, MD

Beyond Weight Loss: Clinical Perspectives on GLP-1s for Inflammatory Dermatoses

As glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reshape the management of obesity and metabolic disease, dermatology clinicians are beginning to explore their relevance far beyond weight loss. GLP-1–based therapies are now drawing attention for their potential anti-inflammatory and immunomodulatory effects—factors highly relevant to chronic dermatologic disease. Drawing on clinical experience and emerging research, clinicians are now examining how GLP-1–based therapies may influence conditions such as psoriasis and hidradenitis suppurativa (HS), signaling a potential clinical shift in the systemic approach to chronic inflammatory skin disorders.

Read more from Karan Lal, DO, MS; Adam Friedman, MD, FAAD; and Steven Daveluy, MD

Exploring Type 2 Inflammation and Psoriasis Management at Horizons in Advanced Practice

At the recent Dermatology Times Horizons in Advanced Practice meeting in Tampa, Florida, multidisciplinary discussions centered on complex inflammatory dermatoses and real-world treatment decision-making. Conference chairs Omar Noor, MD; Lakshi Aldredge, MSN, ANP-BC, DCNP; and Douglas DiRuggiero, DMSc, MHS, PA-C, led 6 interactive breakout groups where dermatology nurse practitioners and physician assistants worked through challenging cases in atopic dermatitis, type 2 inflammation, psoriasis, and more.

In 2 of the focused sessions, Noor guided attendees through case-based reviews of type 2 inflammation and personalized psoriasis management, emphasizing practical communication strategies, comorbidity evaluation, and the evolving landscape of biologic access.

Read more

Click here to view all articles in the January issue.